CoChat

Src inhibitors in breast cancer therapy

Hiscox, Stephen, Nicholson, Robert I · 2008 · Expert Opinion on Therapeutic Targets
Cited by 37

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Recent evidence has established the non receptor tyrosine kinase, Src, as a critical component of multiple signalling pathways that regulate proliferation, survival, angiogenesis and metastasis. Increased levels of Src protein and activity are widely reported in human cancers including breast cancer, and its important role in oncogenic processes makes it a potential target for therapeutic intervention. OBJECTIVE: To review the role of Src kinase in breast cancer and discuss its potential as a therapeutic target. METHODS: Literature citing preclinical and clinical studies with Src inhibitors was reviewed. CONCLUSION: Experimental data with small-molecule inhibitors of Src kinase in breast cancer are encouraging, demonstrating effective suppression in vitro of tumour growth and invasion and inhibition of disease spread in preclinical models in vivo. Recently several Src inhibitors have been tested in Phase I clinical trials where they are well tolerated and demonstrate low toxicity. Overall, these findings suggest that Src inhibitors present a future therapeutic option in the treatment of breast cancer growth and progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14728222.12.6.757

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 37

Metadata

Authors
Hiscox, S., & Nicholson, R. I.
Venue
Expert Opinion on Therapeutic Targets
Published
2008-05-15
Volume
12
Issue
6
Pages
757-767
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2154534312
Cited by
37
References
9
FWCI
2.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Src inhibitors in breast cancer therapy. https://app.cochat.ai/papers/10.1517/14728222.12.6.757
The paper
Hiscox, S., & Nicholson, R. I. (2008). Src inhibitors in breast cancer therapy. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.12.6.757

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.